Intellia Therapeutics (NTLA) vs Alpha Teknova (TKNO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Alpha Teknova (TKNO) has outperformed Intellia Therapeutics (NTLA) over the past year, gaining 77.4% versus a gain of 21.8%. Over five years, TKNO leads with a -63.6% price change compared with -91.2% for NTLA. Intellia Therapeutics is the larger company by market cap ($1.40 billion vs $480.0 million), about 2.9 times the size.
Alpha Teknova converts more of its revenue into profit, with a net margin of -42.6% versus -609.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTLA | TKNO |
|---|---|---|
| Share price | $10.00 | $7.63 |
| Market cap | $1.40B | $479.95M |
| 1-day change | +5.04% | -2.30% |
| YTD return | +11.23% | +100.79% |
| 1-year return | +21.80% | +77.44% |
| 5-year return | -91.16% | -63.63% |
| EPS (TTM) | $-3.35 | $-0.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $67.67M | $40.52M |
| Revenue growth (YoY) | +16.92% | +7.35% |
| Net income (latest FY) | $-412.69M | $-17.26M |
| Gross margin | — | 33.17% |
| Operating margin | -651.67% | -41.90% |
| Net margin | -609.85% | -42.59% |
| 52-week high | $18.48 | $9.48 |
| 52-week low | $8.09 | $1.91 |
| Distance from 52-week high | -45.89% | -19.51% |
| Analyst consensus | buy | none |
| Avg. price target upside | +127.80% | +28.83% |
| Average volume | 5.03M | 437.31K |
| Shares outstanding | 140.36M | 62.90M |
| Employees | 377 | 158 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Intellia Therapeutics is about 2.9 times larger than Alpha Teknova by market value ($1.40B vs $479.95M).
- TKNO has outperformed NTLA by 55.6 percentage points over the past year.
- Alpha Teknova is more profitable, keeping -42.6 cents of every revenue dollar as net income versus -609.9 cents for Intellia Therapeutics.
- Intellia Therapeutics grew revenue faster in its latest fiscal year (+16.92% vs +7.35%).
About Intellia Therapeutics
NTLA stock →Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees
About Alpha Teknova
TKNO stock →Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees
NTLA vs TKNO FAQ
Which is bigger, Intellia Therapeutics or Alpha Teknova?
Intellia Therapeutics (NTLA) is larger, with a market capitalization of $1.40B compared with $479.95M for Alpha Teknova (TKNO).
Which stock has performed better over the past year, NTLA or TKNO?
TKNO returned +77.44% over the past 12 months, compared with +21.80% for NTLA (price return, excluding dividends). Past performance does not predict future results.
Are Intellia Therapeutics and Alpha Teknova in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.